- Home
- CII vs SPRY Comparison
CII vs SPRY Comparison
Compare CII & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CII | SPRY |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 916.6M | 1.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CII | SPRY |
|---|---|---|
| Price | $21.83 | $9.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 92.0K | ★ 889.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | ★ 114.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $89,149,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 297063.34 |
| 52 Week Low | $15.20 | $6.66 |
| 52 Week High | $26.17 | $18.63 |
Technical Indicators
Market Signals| Indicator | CII | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 42.09 |
| Support Level | $21.53 | $8.61 |
| Resistance Level | $22.30 | $10.44 |
| Average True Range (ATR) | 0.27 | 0.44 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 2.15 | 40.31 |
Price Performance
Historical ComparisonAbout CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.